SAREPTA THERAPEUTICS, INC. Proceeds from Long-term Lines of Credit
SAREPTA THERAPEUTICS, INC. (SRPT) reported Proceeds from Long-term Lines of Credit of $235.87 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2021-03-01
- SAREPTA THERAPEUTICS, INC. proceeds from long-term lines of credit for the quarter ending 2018-12-31 was $18.15M, a 15.55% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. proceeds from long-term lines of credit for the quarter ending 2018-09-30 was $44.37M.
- SAREPTA THERAPEUTICS, INC. proceeds from long-term lines of credit for the quarter ending 2018-06-30 was $77.12M.
- SAREPTA THERAPEUTICS, INC. proceeds from long-term lines of credit for the quarter ending 2018-03-31 was $96.23M.
- SAREPTA THERAPEUTICS, INC. proceeds from long-term lines of credit for fiscal 2018 was $235.87M, a 494.02% increase from fiscal 2017.
- SAREPTA THERAPEUTICS, INC. proceeds from long-term lines of credit for fiscal 2017 was $39.71M.
| Period end | Proceeds from Long-term Lines of Credit 3 month | Proceeds from Long-term Lines of Credit 6 month | Proceeds from Long-term Lines of Credit 9 month | Proceeds from Long-term Lines of Credit 12 month |
|---|---|---|---|---|
| 2018-12-31 | $18.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $62.52M derived: sum of 2 quarters · filed 2021-03-01 | $139.64M derived: sum of 3 quarters · filed 2021-03-01 | $235.87M 10-K · filed 2021-03-01 |
| 2018-09-30 | $44.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $121.49M derived: sum of 2 quarters · filed 2019-11-07 | $217.72M 10-Q · filed 2019-11-07 | $233.43M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $77.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $173.35M 10-Q · filed 2019-08-07 | $189.06M derived: sum of 3 quarters · filed 2020-02-26 | |
| 2018-03-31 | $96.23M 10-Q · filed 2019-05-08 | $111.94M derived: sum of 2 quarters · filed 2020-02-26 | ||
| 2017-12-31 | $15.71M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $39.71M 10-K · filed 2020-02-26 | ||
| 2017-09-30 | $24.00M 10-Q · filed 2018-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |